Page 81 - AN-4-2

Advanced Neurology Brain bioavailability of targeted protein degraders

through the murine blood-brain barrier. J Cereb Blood Flow Wang N, Leybaert L. Into rather unexplored terrain-
Metab. 2013;33(12):1983-1992. transcellular transport across the blood-brain barrier. Glia.
2016;64(7):1097-1123.
doi: 10.1038/jcbfm.2013.160
doi: 10.1002/glia.22960
78. Felgenhauer K. Protein size and cerebrospinal fluid
composition. Klin Wochenschr. 1974;52(24):1158-1164. 89. Wu JR, Hernandez Y, Miyasaki KF, Kwon EJ. Engineered
nanomaterials that exploit blood-brain barrier
doi: 10.1007/BF01466734
dysfunction for delivery to the brain. Adv Drug Deliv Rev.
79. Poduslo JF, Curran GL, Berg CT. Macromolecular 2023;197:114820.
permeability across the blood-nerve and blood-brain
barriers. Proc Natl Acad Sci USA. 1994;91(12):5705-5709. doi: 10.1016/j.addr.2023.114820
90. Gray SM, Aylor KW, Barrett EJ. Unravelling the regulation
doi: 10.1073/pnas.91.12.5705
of insulin transport across the brain endothelial cell.
80. Atwal JK, Chen Y, Chiu C, et al. A therapeutic antibody Diabetologia. 2017;60(8):1512-1521.
targeting BACE1 inhibits amyloid-β production in vivo. Sci
Transl Med. 2011;3(84):84ra43. doi: 10.1007/s00125-017-4285-4
91. Roberts RL, Fine RE, Sandra A. Receptor-mediated
doi: 10.1126/scitranslmed.3002254
endocytosis of transferrin at the blood-brain barrier. J Cell
81. Schlachetzki F, Zhu C, Pardridge WM. Expression of the Sci. 1993;104:521-532.
neonatal Fc receptor (FcRn) at the blood-brain barrier. doi: 10.1242/jcs.104.2.521
J Neurochem. 2002;81(1):203-206.
92. Simionescu M, Ghinea N, Fixman A, et al. The cerebral
doi: 10.1046/j.1471-4159.2002.00840.x
microvasculature of the rat: Structure and luminal surface
82. Zhang Y, Pardridge WM. Mediated efflux of IgG molecules properties during early development. J Submicrosc Cytol
from brain to blood across the blood-brain barrier. Pathol. 1988;20(2):243-261.
J Neuroimmunol. 2001;114(1-2):168-172.
93. Stamatovic SM, Sladojevic N, Keep RF, Andjelkovic AV.
doi: 10.1016/s0165-5728(01)00242-9 Blood-brain barrier permeability: From bench to bedside.
83. Catarina Silva M, Nandi G, Donovan KA, et al. Discovery In: Gunel MK, editor. Management of Epilepsy-Research,
and optimization of tau targeted protein degraders enabled Results and Treatment. London: InTech; 2011.
by patient induced pluripotent stem cells-derived neuronal 94. Hervé F, Ghinea N, Scherrmann JM. CNS delivery via
models of tauopathy. Front Cell Neurosci. 2022;16:801179. adsorptive transcytosis. AAPS J. 2008;10(3):455-472.
doi: 10.3389/fncel.2022.801179 doi: 10.1208/s12248-008-9055-2
84. George N, Akhtar J, Al Balushi K, Safi SZ, Azmi SNH, 95. Smith MW, Gumbleton M. Endocytosis at the blood-
Khan SA. The emerging role of proteolysis targeting brain barrier: From basic understanding to drug delivery
chimeras (PROTACs) in the treatment of Alzheimer’s strategies. J Drug Target. 2006;14(4):191-214.
disease. Med Chem Res. 2023;32:601-616.
doi: 10.1080/10611860600650086
doi: 10.1007/s00044-023-03026-w
96. Pemberton S, Galindo DC, Schwartz MW, Banks WA,
85. Kargbo RB. PROTAC compounds targeting α-synuclein Rhea EM. Endocytosis of insulin at the blood-brain barrier.
protein for treating neurogenerative disorders: Front Drug Deliv. 2022;2:1062366.
Alzheimer’s and Parkinson’s diseases. ACS Med Chem Lett. doi: 10.3389/fddev.2022.1062366
2020;11(6):1086-1087.
97. Ben-Zvi A, Lacoste B, Kur E, et al. Mfsd2a is critical for the
doi: 10.1021/acsmedchemlett.0c00192
formation and function of the blood-brain barrier. Nature.
86. Jiang X, Zhou J, Wang Y, et al. PROTACs suppression of 2014;509(7501):507-511.
GSK-3β, a crucial kinase in neurodegenerative diseases. Eur doi: 10.1038/nature13324
J Med Chem. 2021;210:112949.
98. Andreone BJ, Chow BW, Tata A, et al. Blood-brain barrier
doi: 10.1016/j.ejmech.2020.112949
permeability is regulated by lipid transport-dependent
87. Tseng YL, Lu PC, Lee CC, et al. Degradation of suppression of caveolae-mediated transcytosis. Neuron.
neurodegenerative disease-associated TDP-43 aggregates 2017;94(3):581-594.e5.
and oligomers via a proteolysis-targeting chimera. J Biomed doi: 10.1016/j.neuron.2017.03.043
Sci. 2023;30(1):27.
99. Tashima T. Proteolysis-targeting chimera (PROTAC)
doi: 10.1186/s12929-023-00921-7
delivery into the brain across the blood-brain barrier.
88. De Bock M, Van Haver V, Vandenbroucke RE, Decrock E, Antibodies (Basel). 2023;12(3):43.

Volume 4 Issue 2 (2025) 75 doi: 10.36922/an.5140